Patient-Derived Organoids (PDOs): Isolation, Culture, and Clinical Applications

1. Introduction to Patient-Derived Organoid Technology

Patient-derived organoids (PDOs) represent one of the most significant translational applications of organoid technology, bridging the gap between laboratory research and clinical medicine. PDOs are three-dimensional tissue cultures that are established directly from patient biopsy specimens, surgical resections, or fluid samples (such as ascites or pleural effusions), and that recapitulate the histological architecture, genetic profile, transcriptomic landscape, and cellular heterogeneity of the original tumor or normal tissue [1,2]. Unlike traditional cancer cell lines, which are typically derived from a single clonal population and have undergone extensive genetic drift and adaptation to 2D culture conditions, PDOs retain the polyclonal diversity of the parent tumor, preserving the complex interactions between cancer cells, stromal components, and the extracellular matrix that are critical for tumor biology and therapeutic response [3,4].

The concept of PDOs was pioneered by the Clevers laboratory, which in 2011 demonstrated that human colorectal cancer tissue could be cultured as organoids using the same growth factor cocktail (EGF, Noggin, R-spondin 1) that was originally developed for normal intestinal organoids [5]. Since this foundational work, PDO technology has been extended to virtually all major cancer types, including colorectal, gastric, pancreatic, breast, prostate, lung, liver, ovarian, bladder, and brain cancers, as well as to non-malignant tissues such as normal breast, prostate, and pancreatic ductal epithelium [1,2,6]. The establishment of large-scale PDO biobanks (such as the Human Cancer Models Initiative, the HUB Organoid Platform, and the European Organoid Resource) has created unprecedented opportunities for translational research, enabling systematic drug screening, biomarker discovery, and the identification of genotype-phenotype correlations across diverse patient populations [6,7].

The clinical significance of PDOs lies in their ability to serve as patient-specific tumor avatars for ex vivo drug screening. Multiple prospective and retrospective studies have demonstrated that PDO drug responses correlate with patient clinical outcomes with high concordance (typically 70–90%), supporting the use of PDOs as predictive biomarkers for treatment selection [1,8,9]. The typical workflow for clinical PDO applications involves: (1) collection of tumor tissue during biopsy or surgery; (2) establishment of PDO cultures within 2–4 weeks; (3) expansion and validation of PDO lines; (4) high-throughput drug screening against standard-of-care and investigational therapies; (5) generation of a drug response profile; and (6) integration of the profile with clinical and genomic data to guide treatment decisions. This entire workflow can be completed within 4–8 weeks, which is clinically actionable for second-line or later therapy decisions [1,2,8].

This article provides a comprehensive overview of PDO isolation, culture, and clinical applications, with detailed protocols, technical parameters, and quality assurance measures validated for translational research and precision oncology.

2. Fundamental Principles of PDO Culture

PDO culture relies on the same fundamental principles as normal organoid culture: the provision of appropriate niche signals, embedding in a 3D extracellular matrix, and maintenance of stem cell populations that can self-renew and differentiate. However, tumor-derived organoids often exhibit altered growth factor dependencies compared to their normal counterparts, reflecting the oncogenic mutations and signaling pathway alterations that drive tumor growth and survival [3,4].

Key biological principles that govern PDO culture include:

• Oncogene-Driven Growth Factor Independence: Tumors with activating mutations in Wnt pathway components (such as APC loss or β-catenin activating mutations in colorectal cancer) or in receptor tyrosine kinase pathways (such as KRAS mutations in pancreatic and colorectal cancer) may exhibit reduced dependence on exogenous Wnt or EGF signaling. For example, colorectal cancer PDOs with APC mutations often do not require supplemental Wnt3a in the culture medium, as the constitutive activation of Wnt signaling downstream of the mutation provides autonomous stem cell maintenance [5,10].
• Stromal and Microenvironmental Signals: The tumor microenvironment contains fibroblasts, immune cells, endothelial cells, and extracellular matrix components that provide signals that are largely absent in standard PDO culture. This microenvironmental simplification can alter tumor cell behavior, drug responses, and resistance mechanisms. Emerging PDO culture systems incorporate stromal components (such as cancer-associated fibroblasts, tumor-associated macrophages, or extracellular matrix proteins) to better recapitulate the in vivo tumor context [3,11].
• Selection Pressures During Culture: The process of establishing PDOs from tumor tissue involves selective pressure for cells that can survive and proliferate under the specific culture conditions. This can lead to the loss of rare subclones or the enrichment of aggressive, rapidly proliferating cell populations. Long-term PDO culture may also select for cells with additional mutations that confer a growth advantage in vitro. Regular genetic monitoring and early-passage banking are essential to minimize culture-induced drift [1,4].
• Tissue-Specific Niche Requirements: Different tumor types require distinct combinations of growth factors, inhibitors, and matrix components for successful PDO establishment. For example, pancreatic ductal adenocarcinoma (PDAC) PDOs require FGF10 and A83-01 in addition to the standard EGF, Noggin, and R-spondin 1, while breast cancer PDOs may require additional factors such as hydrocortisone and insulin [2,12]. The optimization of culture conditions for each tumor type is an active area of research and is critical for improving PDO establishment rates and biological fidelity.

3. Tissue Procurement, Processing, and Crypt/Cell Isolation

3.1 Collection and Transport

The quality of the starting tissue is the single most important determinant of PDO establishment success. The following protocol should be followed to ensure optimal tissue viability and sterility:

1. Collect tissue specimens (endoscopic biopsy, needle biopsy, surgical resection, or fluid sample) in a sterile container containing 10–20 mL of organoid collection medium. The collection medium consists of Advanced DMEM/F12 + 10% fetal bovine serum (FBS) + 1% Penicillin/Streptomycin + 100 µg/mL Primocin (InvivoGen, ant-pm-1) + 10 µM Y-27632 (ROCK inhibitor). The FBS and Y-27632 improve cell survival during transport, while Primocin provides broad-spectrum antimicrobial coverage against bacteria, fungi, and mycoplasmas [1,13].
2. Transport the specimen on ice (4°C) and process within 6 hours for optimal viability. If processing must be delayed, the tissue can be stored at 4°C for up to 24 hours with minimal viability loss. For delays exceeding 24 hours, cryopreservation in 10% DMSO + 10% FBS + 80% complete medium is recommended, though viability may be reduced by 20–30% upon thawing [13].
3. Record the tissue type, patient identifier, collection time, and any relevant clinical information (diagnosis, prior treatments, tumor stage) in the laboratory information management system (LIMS) or sample tracking database.

3.2 Tissue Dissection and Dissociation

The dissociation protocol must be optimized for the specific tissue type and tumor histology. The following protocols are adapted from established methods for epithelial and solid tumors [1,5,13].

Epithelial Tumors (Colorectal, Gastric, Pancreatic, Breast):

1. Transfer the tissue to a sterile 10 cm petri dish containing ice-cold PBS.
2. Using sterile scalpels, scissors, and forceps, dissect the tumor tissue from adjacent normal tissue (if present) and remove necrotic areas, blood clots, and fatty tissue. Cut the tumor tissue into 1–2 mm fragments.
3. Wash the fragments extensively with ice-cold PBS (10–15 washes) to remove blood, mucus, and debris. This step is critical for preventing bacterial contamination and for removing inhibitors that may be present in the tissue.
4. For tumors with glandular architecture (colorectal, gastric): Incubate the tissue fragments in 10 mM EDTA in PBS at 4°C for 30–90 minutes with gentle rocking. The EDTA disrupts the basement membrane and releases epithelial crypts or glandular structures. After EDTA incubation, transfer the fragments to a fresh tube with PBS and shake vigorously or pipette repeatedly to release the epithelial structures. Pass through a 70–100 µm cell strainer and collect by centrifugation at 200–300 × g for 5 minutes at 4°C [5,13].
5. For solid tumors requiring enzymatic digestion (pancreatic, breast, prostate): Incubate the tissue fragments in digestion buffer containing Liberase (50–100 µg/mL, Roche, 5401020001) or Collagenase II (200 U/mL, Worthington, LS004174) + Dispase (0.5 mg/mL, STEMCELL Technologies, 07913) + DNase I (0.1 mg/mL, Sigma-Aldrich, DN25) in DMEM/F12 at 37°C for 30–60 minutes with gentle agitation (orbital shaker at 100 rpm). Monitor the digestion under a microscope and stop when cell clusters of 10–50 cells are visible. Over-digestion can destroy stem cells and reduce organoid formation efficiency [1,12].
6. Stop the digestion by adding an equal volume of cold DMEM/F12 + 10% FBS. Pass the digested suspension through a 70 µm cell strainer to remove undigested fragments. Centrifuge at 200–300 × g for 5 minutes at 4°C. Resuspend the pellet in cold Matrigel for plating.

Brain Tumors (Glioblastoma, Medulloblastoma):

1. Process fresh tumor tissue within 2 hours of surgical resection.
2. Mince the tissue into 1 mm fragments and digest with papain (20 U/mL, Worthington, LS003119) + DNase I (0.1 mg/mL) at 37°C for 15–30 minutes.
3. Triturate gently with a fire-polished Pasteur pipette to dissociate the tissue into single cells and small clusters.
4. Filter through a 40 µm strainer and centrifuge at 300 × g for 5 minutes.
5. Resuspend in neurosphere medium (DMEM/F12 + B27 + N2 + EGF 20 ng/mL + FGF2 20 ng/mL + heparin 5 µg/mL) and culture in low-attachment flasks for 3–7 days to enrich for tumor stem cells before organoid formation [14,15].

4. Culture Media Formulation by Tumor Type

The formulation of PDO culture media must be tailored to the specific tumor type, taking into account the oncogenic mutations, growth factor dependencies, and stromal interactions that characterize each cancer. The following formulations are based on established protocols and have been validated for clinical and research applications [1,2,5,10,12].

4.1 Colorectal Cancer (CRC) PDO Medium

Base: Advanced DMEM/F12 (Gibco, 12634010)

Supplements:

• 2 mM GlutaMAX
• 10 mM HEPES
• 1× B27 supplement (without vitamin A)
• 1× N2 supplement
• 1.25 mM N-acetylcysteine
• 10 mM Nicotinamide
• 10 nM Gastrin (human)
• 50 ng/mL EGF (recombinant human)
• 100 ng/mL Noggin (recombinant human)
• 500 ng/mL R-spondin 1 (recombinant human)
• 500 nM A83-01
• 10 µM SB202190
• 100 ng/mL Wnt3a (recombinant human) – required for CRC PDOs with wild-type APC; can be omitted for APC-mutant tumors [5,10]

4.2 Pancreatic Ductal Adenocarcinoma (PDAC) PDO Medium

Base: Advanced DMEM/F12

Supplements:

• 2 mM GlutaMAX
• 10 mM HEPES
• 1× B27 supplement
• 1.25 mM N-acetylcysteine
• 10 mM Nicotinamide
• 50 ng/mL EGF
• 100 ng/mL Noggin
• 500 ng/mL R-spondin 1
• 500 nM A83-01
• 10 µM SB202190
• 100 ng/mL FGF10 (recombinant human) – promotes PDAC progenitor expansion
• 10 µM Y-27632 (added for the first 48 hours only) [12,16]

4.3 Gastric Cancer PDO Medium

Base: Advanced DMEM/F12

Supplements:

• 2 mM GlutaMAX
• 10 mM HEPES
• 1× B27 supplement
• 1.25 mM N-acetylcysteine
• 10 mM Nicotinamide
• 10 nM Gastrin (human) – particularly important for gastric epithelial proliferation
• 50 ng/mL EGF
• 100 ng/mL Noggin
• 500 ng/mL R-spondin 1
• 500 nM A83-01
• 10 µM SB202190 [17]

4.4 Breast Cancer PDO Medium

Base: Advanced DMEM/F12

Supplements:

• 2 mM GlutaMAX
• 10 mM HEPES
• 1× B27 supplement
• 1.25 mM N-acetylcysteine
• 10 mM Nicotinamide
• 50 ng/mL EGF
• 100 ng/mL Noggin
• 500 ng/mL R-spondin 1
• 500 nM A83-01
• 10 µM SB202190
• 5 µM Y-27632 (first 48 hours)
• 1 µM hydrocortisone (Sigma-Aldrich, H0888) – supports hormone receptor-positive breast cancer organoid growth
• 10 µg/mL insulin (Sigma-Aldrich, I1882) – promotes epithelial proliferation [18]

4.5 Glioblastoma PDO Medium

Base: DMEM/F12 + Neurobasal Medium (1:1)

Supplements:

• 1× B27 supplement (without vitamin A)
• 1× N2 supplement
• 2 mM GlutaMAX
• 20 ng/mL EGF
• 20 ng/mL FGF2 (basic fibroblast growth factor)
• 5 µg/mL heparin (Sigma-Aldrich, H3149)
• 10 µM Y-27632 (first 48 hours)
• 1% Penicillin/Streptomycin
• Optional: 10 ng/mL PDGF-AA (R&D Systems, 221-AA) for mesenchymal subtype glioblastomas [14,15]

5. Embedding, Culture Maintenance, and Passaging

5.1 Plating and Initial Culture

1. Resuspend the isolated tumor cell clusters in cold Matrigel at a density of 500–5,000 cells per 30 µL droplet (exact density depends on cellularity, tissue type, and the proportion of viable tumor cells). For biopsy specimens with limited material, the entire cell suspension may be plated in 1–2 wells.
2. Plate 30–50 µL Matrigel droplets in pre-warmed 24-well plates, ensuring that the droplets do not touch the well sides.
3. Polymerize at 37°C for 10–15 minutes.
4. Add 500 µL of complete PDO medium per well.
5. Maintain at 37°C, 5% CO2. Change the medium every 2–3 days.
6. Monitor organoid formation by brightfield microscopy. Successful PDOs typically appear as small, spherical structures within 3–7 days. Some tumor types (particularly pancreatic and breast cancers) may require 2–4 weeks for visible organoid formation [1,13].

5.2 Passaging and Expansion

1. PDOs are typically passaged when they reach 80–100 µm in diameter or when the Matrigel dome is filled with organoids (typically every 7–14 days).
2. Mechanically disrupt the Matrigel and organoids in cold Advanced DMEM/F12 by scraping with a pipette tip and vigorous pipetting.
3. For dissociation, incubate with TrypLE Express at 37°C for 5–10 minutes, then pipette vigorously to fragment the organoids into 10–50 cell clusters. For some tumor types (particularly brain tumors), mechanical dissociation without enzymes is preferred to preserve cell viability.
4. Pass the fragmented organoids through a 40–70 µm strainer to select appropriate fragment sizes. Large fragments may not re-embed efficiently, while single cells may have poor survival.
5. Centrifuge at 200–300 × g for 5 minutes at 4°C.
6. Resuspend the pellet in cold Matrigel and re-plate at a 1:2 to 1:4 ratio [1,13].

6. Quality Control and Authentication

6.1 Histological Validation

Compare PDO histology to the parent tumor by hematoxylin and eosin (H&E) staining of formalin-fixed, paraffin-embedded (FFPE) sections. PDOs should recapitulate the glandular architecture, nuclear pleomorphism, mitotic activity, and stromal characteristics of the original tumor. For example, colorectal cancer PDOs should exhibit glandular structures with varying degrees of differentiation, while pancreatic cancer PDOs should show duct-like structures with mucin production and desmoplastic stroma [1,4].

6.2 Genetic Profiling

Perform whole-exome sequencing (WES) or targeted next-generation sequencing (NGS) using cancer gene panels to confirm that PDOs retain the driver mutations (KRAS, TP53, APC, PIK3CA, BRAF, EGFR, etc.) present in the parent tumor. Single-nucleotide polymorphism (SNP) array analysis can detect copy number alterations and chromosomal instability. For brain tumors, methylation profiling (e.g., using the MNP classifier) can confirm tumor subtype classification [4,14].

6.3 Short Tandem Repeat (STR) Profiling

Authenticate PDO lines by STR profiling and match the profile to the patient tissue or a blood sample. STR profiling is essential for preventing cross-contamination between PDO lines and for ensuring the correct assignment of drug response data to the corresponding patient [1,13].

6.4 Mycoplasma Testing

Test PDO cultures monthly for mycoplasma contamination using PCR-based detection, luminescence-based assays (MycoAlert, Lonza), or direct culture methods. Mycoplasma contamination is a serious concern in PDO culture because it can alter drug responses and compromise the validity of clinical predictions [1,13].

6.5 Karyotype Analysis

Monitor for chromosomal stability by G-banding karyotyping or SNP array analysis. While some degree of aneuploidy and chromosomal instability is expected in tumor-derived cultures, significant drift from the parent tumor karyotype should be documented. For normal tissue-derived organoids, normal diploid karyotypes should be maintained [1,4].

7. Clinical Applications of PDOs

7.1 Personalized Drug Screening and Predictive Biomarkers

The most promising and clinically validated application of PDOs is ex vivo drug screening to predict patient response to therapy. The rationale is that PDOs, as patient-specific tumor avatars, will respond to drugs in a manner that reflects the in vivo response of the patient's tumor. This approach has been validated across multiple cancer types with high concordance rates:

• Colorectal Cancer: PDOs predicted responses to 5-fluorouracil (5-FU), oxaliplatin, irinotecan, and targeted therapies (cetuximab, panitumumab) with 80–90% accuracy when compared to patient clinical outcomes [8,9].
• Pancreatic Cancer: PDAC PDO drug profiles correlated with patient survival and chemotherapy response. PDOs from patients who responded to FOLFIRINOX or gemcitabine/nab-paclitaxel showed significantly higher sensitivity to these regimens in vitro compared to PDOs from non-responders [12,16].
• Breast Cancer: PDOs retained HER2 receptor status, estrogen receptor status, and tamoxifen sensitivity, enabling the selection of targeted therapies. Triple-negative breast cancer PDOs were used to identify patient-specific responses to platinum agents and PARP inhibitors [18].
• Glioblastoma: PDOs predicted responses to temozolomide, EGFR inhibitors (erlotinib), and CDK4/6 inhibitors (palbociclib). Importantly, PDOs recapitulated the intratumoral heterogeneity of glioblastoma, with different regions of the same tumor generating PDOs with distinct drug sensitivities [14,15].

The typical drug screening protocol involves plating PDOs in 96-well or 384-well formats, exposing them to drug panels for 3–7 days, and assessing viability using CellTiter-Glo (Promega), ATP-based assays, or live/dead staining. Drug response is quantified as the area under the dose-response curve (AUC) or the half-maximal inhibitory concentration (IC50), and these metrics are compared to clinical response data to establish predictive models [1,8].

7.2 PDO-Directed Clinical Trials and Prospective Studies

Several prospective clinical trials are evaluating PDO-guided treatment selection in real-world clinical settings. The "PDOx" trial and similar initiatives aim to establish PDOs within clinically actionable timeframes (4–8 weeks) and use the results to guide second-line or later therapy decisions. In these trials, patients with refractory or metastatic cancers undergo tumor biopsy, and the resulting PDOs are screened against a panel of standard-of-care and investigational therapies. The patient is then treated with the drug or combination that showed the highest efficacy in the PDO screen [1,8].

The Dutch PDO trial for metastatic colorectal cancer demonstrated that PDO screening could identify effective therapies in patients who had progressed on multiple prior lines of treatment, with a progression-free survival benefit compared to physician-choice chemotherapy [8]. Similar trials are underway for pancreatic cancer, breast cancer, and glioblastoma.

7.3 Immunotherapy and Immune-Cell Co-Culture Models

PDOs can be co-cultured with autologous immune cells to model tumor-immune interactions and to predict the efficacy of immunotherapies, including checkpoint inhibitors, adoptive cell therapies, and cancer vaccines. Key co-culture models include:

• Tumor-Infiltrating Lymphocyte (TIL) Co-Culture: TILs are expanded from tumor tissue and co-cultured with PDOs in the presence of interleukin-2 (IL-2, 100 U/mL). The co-culture system can be used to assess the cytotoxic activity of TILs against autologous tumor organoids and to evaluate the effects of checkpoint inhibitors (anti-PD-1, anti-CTLA-4) on TIL-mediated killing [11,19].
• Air-Liquid Interface (ALI) Tumor Organoid Culture: Neal and colleagues developed an ALI method for co-culturing tumor epithelial organoids with autologous tumor-infiltrating lymphocytes. In this system, the PDOs are grown at an air-liquid interface, which preserves the original tumor T-cell receptor repertoire and allows for the accurate modeling of immune checkpoint blockade. This method has been used to demonstrate that anti-PD-1 antibodies enhance the cytotoxic activity of autologous T cells against tumor organoids [11,19].
• CAR-T Cell Therapy Testing: PDOs can be used to pre-screen patient tumors for chimeric antigen receptor T (CAR-T) cell therapy efficacy. GFP-labeled CAR-T cells are co-cultured with PDOs, and tumor cell killing is monitored by live imaging and viability assays. This approach has been validated for colorectal cancer and glioblastoma [20].

7.4 PDO Biobanking and International Registries

Large-scale PDO biobanks have been established as critical infrastructure for translational cancer research. These biobanks serve as living repositories of patient-specific tumor models that are linked to clinical metadata, genomic profiles, and drug response data. Key international biobanking initiatives include:

• Human Cancer Models Initiative (HCMI): A collaborative effort between the US National Cancer Institute, Cancer Research UK, and the Hubrecht Institute to generate and characterize hundreds of cancer organoid models across diverse tumor types [6].
• HUB Organoids (Netherlands): The largest academic organoid biobank, containing over 1,000 PDO lines from colorectal, pancreatic, breast, prostate, and other cancers, with extensive genomic and drug screening annotations [6].
• European Organoid Resource (EurOPDX): A European initiative that coordinates the distribution of patient-derived xenograft (PDX) and PDO models for cancer research, with standardized quality control and data sharing protocols [7].

These biobanks function as living resources that enable reproducible research across laboratories, accelerate the identification of biomarkers and therapeutic targets, and provide preclinical models for drug development and clinical trial design [6,7].

8. Challenges, Limitations, and Future Directions

Despite the remarkable promise of PDO technology, several significant challenges remain that limit its widespread clinical adoption and research utility:

• Establishment Rates and Success Rates: PDO establishment rates vary widely by tumor type, ranging from 30% for prostate and breast cancers to 90% for colorectal cancers. The reasons for failure include insufficient viable tumor cells in the biopsy, extensive necrosis or fibrosis, microbial contamination, and the lack of optimized culture conditions for certain tumor subtypes. Improvements in tissue processing, culture media formulation, and matrix selection are needed to increase success rates across all tumor types [1,2].
• Culture Time and Clinical Actionability: The time required to establish PDOs (2–4 weeks) and expand them to sufficient numbers for drug screening (additional 2–4 weeks) may exceed the window for clinical decision-making in patients with rapidly progressing cancers. For first-line therapy decisions, genomic profiling (which can be completed in 1–2 weeks) may be more clinically actionable than PDO-based screening. However, for second-line or later therapy decisions, and for patients with rare or refractory cancers, the 4–8 week PDO workflow is often clinically acceptable [1,8].
• Absence of Stroma and Microenvironment: Standard PDO cultures lack the tumor stroma (cancer-associated fibroblasts, immune cells, vasculature, and extracellular matrix) that profoundly influences tumor growth, drug penetration, and therapeutic resistance. This limitation means that PDOs may not accurately predict responses to drugs that target the microenvironment (such as anti-angiogenic agents or stromal-targeting therapies) or to therapies that depend on immune-mediated mechanisms (such as checkpoint inhibitors) [3,11].
• Cost and Technical Expertise: PDO culture is more expensive and technically demanding than standard 2D cell culture. The costs of growth factors, Matrigel, and specialized media can exceed $500–$1,000 per PDO line for establishment and expansion. Furthermore, PDO culture requires skilled personnel with expertise in tissue processing, sterile technique, and quality control. These factors limit the scalability of PDO technology and its accessibility to resource-limited settings [1,2].

Emerging solutions to these challenges include:

• Organoid-stromal co-cultures that incorporate cancer-associated fibroblasts, macrophages, and endothelial cells
• Organoid-on-chip systems with vascular perfusion and immune cell circulation
• Automated, high-throughput PDO culture and screening platforms that reduce labor costs and increase reproducibility
• Machine learning-based predictive models that integrate PDO drug response data with genomic and clinical features to improve prediction accuracy [3,11,18]

9. Conclusion

Patient-derived organoids represent a paradigm shift in precision oncology, enabling the creation of patient-specific tumor avatars for drug screening, biomarker discovery, and clinical decision support. The high concordance between PDO drug responses and patient clinical outcomes, demonstrated across multiple cancer types, supports the integration of PDO technology into clinical workflows for personalized treatment selection. By following standardized protocols for tissue processing, culture optimization, and quality control, researchers and clinicians can establish PDO biobanks that bridge basic research and clinical practice, accelerating the translation of scientific discoveries into improved patient outcomes.

GBiowit provides comprehensive PDO establishment services, including custom media formulation for specific tumor types, Matrigel and defined matrix alternatives, cryopreservation and banking solutions, and integrated high-throughput drug screening platforms. Our experienced technical team can assist with protocol optimization, troubleshooting, and the development of custom PDO applications for translational research and precision medicine initiatives.